BridgeMD
Dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps: the effect on comorbid eosinophilic otitis media
EU CTIS ID: 2023-508068-31-00
What this study is testing
This study aims to determine the effect of dupilumab on ear symptoms and auditory function in chronic rhinosinusitis with nasal polyp and eosinophilic otitis media patients
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Retrospective part: - CRSwNP+EOM patients having started dupilumab treatment from 2020 onwards with sufficient data to meet the primary endpoint (otologic questionnaires [OQUA and DCES] at baseline and at least at 6 or 12 months of treatment)
- Prospective part: adult (18 years and above) CRSwNP+EOM patients starting dupilumab treatment as part of regular clinical care
You likely can't join if
- Prospective part: not being capable of filling in study questionnaires
- Prospective part: not being able to undergo audiometry
- Prospective part: <18 years of age
- Retrospective part: no consent to use the clinical data
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.